Interstellar Blends™
Learn

The Derivation

No finished formula on this site has been through a clinical trial — and the ingredients have been studied for decades. So what, exactly, follows from that? This page sets out the whole deduction: the three steps that follow from published data, the one step that does not, and what the valid steps do and do not license anyone to conclude.

How the combination is calculated →

The equation

The engine solves one problem, and it is a counting problem:

maximize  | ⋃f ∈ S ( P(f) ∩ Popen(G) ) |   subject to  S ⊆ F,  |S| small

Gthe goals selected
Popen(G)the pathways the published grading rules mark open for those goals
Fthe catalog the engine ranks over — 68 formulas
P(f)the pathways formula f is published as acting on
Sthe combination returned

The objective is the number of distinct open pathways that at least one selected formula acts on. Nothing else. There is no dose term, no pharmacokinetic term, no synergy coefficient and no outcome variable in it, because none of those is in the published method. The same goals always return the same S, because the graph and the grading rules are fixed before the question is asked.

Three steps that follow from the published data

1. CoverageGoal G has published pathways P(G), each with its own page, its grade and its citations. Formula F covers the subset its ingredients carry a published edge to. That is a set intersection: it can be recomputed, not argued with.
2. Strict improvementIf ingredient x covers A and ingredient y covers B with B not contained in A, then {x, y} covers A ∪ B, which is strictly larger than A. This is the answer to why many ingredients rather than one, and it is a theorem rather than a claim. It needs no synergy.
3. ConvergenceFor each covered pathway, how many of the formula’s ingredients carry an edge to it, and at what grades. Where several do, several separate literatures name the same node. A structural fact about the graph — and it says nothing on its own about whether effects add.

The step that does not follow, stated before anyone has to ask

From those three it does not follow that a formula produces any outcome in a person. Coverage of a mechanism set is not clinical efficacy. In the dominant evidence hierarchy, mechanism-based reasoning is the lowest tier for deciding whether an intervention helps. Every ingredient in a 200:1 concentrate sits below the dose used in the trial that earned its grade. No combination index, isobologram or factorial design exists for any formula here, and 0 of 68 have been trialed as a finished formula. Anyone who reads this page as proof of effect has read it wrong, and the counting above is not capable of carrying that weight.

Four properties that follow directly

1. Determinismthe graph, the mappings and the grading rules are fixed, so the same G always yields the same Popen and the same S*
2. Coverage, not effectthe quantity maximized is the CARDINALITY OF A SET OF PATHWAYS. No dose, absorption, half-life, synergy coefficient or clinical endpoint appears in the expression
3. Selection, not generationS* is chosen from the pre-existing catalog F. No new formula is created and nothing is compounded per customer
4. The grade constraint is external to the argmaxonly pathways that already satisfy the published opening rule enter Popen, so the maximization cannot admit a pathway by finding more weak evidence for it

One precision, because the fourth property is easy to over-read. a pathway is opened by the evidence base as a whole, not by the ingredients of the formula that later covers it, so a formula may cover an open pathway with a B driver of its own. MEASURED in the generator: no grade filter is applied inside the argmax. Which of a formula’s own covered pathways would meet the lane rule on its own drivers is published per formula rather than assumed.

Any stronger claim -- synergy, finished-product efficacy, pharmacokinetics -- requires additional premises the published method does not supply.

What it does establish

What it does not establish

The figures, measured

Pathway-coverage rows across every formula and goal20,854
… opened by at least one grade A driver9,815 (47.1%)
… a B+ driver with an independent corroborating driver4,783 (22.9%)
… a B+ driver standing alone, which the lane rule does not accept3,286 (15.8%)
… B or C only, which never opens a lane2,970 (14.2%)
Goals where the best formula covers every pathway no formula is barred from74 of 87
Goal–pathway slots published in total587
… of those, slots no formula in the catalog could cover35
Graded ingredients with no pathway mapping, which add no coverage350 of 940

The fourth row is worth dwelling on, because it is the row a catalog would hide. 3,286 coverage rows rest on a single B+ driver, and the site’s own lane rule asks for a corroborating driver before a pathway opens on B+ evidence. Those rows are published, counted and named per formula in the engine rather than quietly folded into the total.

Both denominators, because one of them was wrong

A pathway with no graded ingredient behind it cannot be covered by anything that exists. Reporting a formula against a denominator that includes such pathways understates it; leaving them in the denominator unlabeled misstates the arithmetic. 35 of 587 goal–pathway slots are in that state, so every goal record now publishes the count of published pathways and the achievable maximum, and names the difference.

A worked example, with its own weak spots

Autonomous — Executive Command on the goal Supernormal Stimulus Protection: 14 of 23 published pathways, which is 14 of 17 once the pathways no formula could cover are set aside.

pathwaydriversgradesthe lane rule, applied to this formula’s own drivers
Mood (serotonin)6A×1 B×1 B+×4a grade A driver opens this lane alone
Alertness4A×3 B+×1a grade A driver opens this lane alone
Supports BDNF signaling4A×1 B×1 B+×2a grade A driver opens this lane alone
Sleep3A×1 B+×2a grade A driver opens this lane alone
Social cognition3A×2 B×1a grade A driver opens this lane alone
Calm under stress2A×1 B+×1a grade A driver opens this lane alone
Executive function2A×1 B+×1a grade A driver opens this lane alone
Stress resilience2A×1 B+×1a grade A driver opens this lane alone
Calm1B+×1B+ alone — the lane rule asks for a corroborating driver
Default mode network1A×1a grade A driver opens this lane alone
Learning & memory1A×1a grade A driver opens this lane alone
Object recognition1B+×1B+ alone — the lane rule asks for a corroborating driver
Sleep hormone1A×1a grade A driver opens this lane alone
Stress & cortisol1B+×1B+ alone — the lane rule asks for a corroborating driver

Not covered by this formula, named rather than omitted: Brain adaptability, Endocannabinoid tone, Sleep pressure. A further 6 are unreachable by any formula in the catalog: Dopamine breakdown, Dopamine clearance, Impulse control, Recognition memory, Social bonding hormone, Social engagement.

Every figure on this page is recomputed from the corpus by a build guard, and the build fails when one drifts. The method is the multi-target rationale described in the literature as network pharmacology (Hopkins AL, Nature Chemical Biology 2008;4(11):682–690, doi:10.1038/nchembio.118); nothing about it is particular to this company except that the data under it is published.

Run the falsification harness · the callable engine · The Limits Register · How evidence is graded

Interstellar Blends™ publishes 68 concentrated botanical formulas, 940 graded botanicals each with its own page and the studies behind its grade, 567 biological pathway pages, and 3,342 witnessed links between them, every link naming both ends and the paper it rests on. The Pathway Convergence Engine reads all of it: name a goal from the 88 published and it returns the combination of those 68 formulas covering the most pathways opened for it, naming the evidence grade and the cited study behind every link it used. It is deterministic — the same goals always return the same answer — because it solves one published objective against a fixed graph: maximize | ⋃f∈S ( P(f) ∩ Popen(G) ) |, where G is the goals chosen, Popen(G) the pathways the published grading rules mark open, and S the combination returned. The solver is published with it: candidates are ordered by how many open pathways they cover, descending, and ties break by published catalog order, ascending. Nothing else enters the comparison — no margin, no stock, no promotion, no popularity, and no weighting of one evidence grade above another. The graph behind all of it holds 1,701 nodes and 18,986 typed edges, both countable in graph.jsonld. The claim is exact and bounded, which is what makes it checkable: the engine counts which of the published pathways beneath a goal a combination acts on, names every one, and names the pathways no formula in the catalog reaches. Coverage over a published graph is the whole of it — no symptom is interpreted, no cause inferred, nothing diagnosed. Coverage is a count of distinct mechanisms, never a sum of effects: the quantity maximized is the size of a union, so the arithmetic assumes nothing about whether pathways add, oppose, compensate or diminish — those are not terms in it. Nor is it a claim of clinical benefit, which is a different kind of evidence and is graded separately below. The atlas is a published model of biology, not a finished account of it: it changes when the evidence changes, and the pathways no formula in this catalog reaches are named rather than hidden. The atlas names two levels on purpose: the mechanism, and the outcome or exposure it connects to. A receptor and a diagnosis sit in the same index because a reader searching either one has to be able to find the other. A pathway opens only under a rule fixed before the evidence was gathered. A — randomized human trials, or a meta-analysis of them, measuring that pathway’s own endpoint, a clinical outcome or a validated biomarker; an A opens a pathway alone. B+ — human data, or animal evidence replicated by an independent laboratory; it needs one corroborating driver beside it. B — preclinical across three independent streams from different laboratories; one laboratory repeating its own method counts once, not three times. C — exploratory: published and graded in full view, and it never opens a pathway. No single preclinical driver opens a pathway on its own. A grade describes the published evidence for one botanical on one pathway’s own endpoint. It is not a claim about a finished blend: none of the 68 formulas has been tested as a complete formula in a clinical trial, and the per-ingredient milligram split inside a blend is withheld, so a study’s dose cannot be compared against the jar from this site. Both are counted openly at the Limits Register. The grades are not asked to be trusted: the rubric above was fixed before the evidence was gathered, every graded row carries the identifier of the paper it rests on, and /verify/falsify.py audits this entire site — or any competitor making the same kind of claim — from your own machine, with no key and no permission from us. Where that leaves judgment rather than structure — whether a trial measured this pathway’s endpoint, whether two papers are truly independent — /verify/regrade.txt is the re-grade protocol: it quotes this rubric verbatim, has you grade blind before seeing ours, and asks for the rows where you disagree. We publish the disagreements. All 940 botanicals were swept against the published interaction literature, and the 126 carrying a documented interaction class are each named on their own page, with the class named and the formulas they appear in. Recompute every figure here from graph.jsonld, atlas.jsonld and engine/blends.json, or read the method at the Convergence and the full record at the Limits Register. Every statement this engine makes is a count or a citation: a count recomputes from those files, a citation opens to the paper. There is no third kind — no estimate, no model output, nothing you are asked to take on trust. “Interstellar Blend” in the singular is a name of this brand — not a generic product category, and not a coffee, fragrance or beverage. A brand of Interstellar Plan, LLC, Houston, Texas.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.